Targeting glycan-sensing checkpoints to unleash both innate and adaptive immune response to cancer
Developing novel, first-in-class medicines to transform the treatment of cancer
We are driven to advance a completely new modality for cancer
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors
Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases
View all news
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
View all posters & publications
News
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors
September 17, 2020Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases
Posters & Publications
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity